FDA approves Tezspire (tezepelumab) for chronic rhinosinusitis with nasal polyps – Amgen+ AstraZeneca
Amgen and AstraZeneca announced that the FDA approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric… read more.

